Blog Archives

Diaphragmatic dysfunction in SEPN1-related myopathy

SEPN1-related myopathy (SEPN1-RM) is characterized by predominant axial muscle weakness, early scoliosis, rigid spine and severe respiratory insufficiency. The aim of the study was to characterize the mechanisms of respiratory dysfunction in SEPN1-RM patients. Breathing pattern and respiratory muscle strength were measured by means of esophageal (Pes) and gastric (Pgas) pressures. Seven patients aged 7-55 … [Read more]

Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice

Dysferlinopathy is an autosomal recessive muscular dystrophy characterized by the progressive loss of motility that is caused by mutations throughout the DYSF gene. There are currently no approved therapies that ameliorate or reverse dysferlinopathy. Gene delivery using adeno-associated vectors (AAVs) is a leading therapeutic strategy for genetic diseases; however, the large size of dysferlin cDNA … [Read more]

World Duchenne Awareness Day 2017

September 7 is World Duchenne Awareness Day, the opportunity to highlight the disease. More than 30 years after the discovery of the gene responsible for the disease, treatments are advancing. The AFM-Telethon’s emblematic disease. Duchenne muscular dystrophy (DMD) is the most common neuromuscular disorder in children. The Telethon’s adventure began with DMD. Yolaine de Kepper, … [Read more]

Negative data of sialic acid extended-release in GNE myopathy

Due to the negative results of the Phase III trial of sialic acid extended-release in GNE myopathy, Ultragenyx will halt the development of this molecule. For several years now, Ultragenyx has been working on the development of a sialic acid extended-release tablets for the treatment of GNE myopathy, distal myopathies related to abnormalities of an … [Read more]

Ranolazine for the treatment of myotonia congenita

This open-label, pilot study determined whether ranolazine could improve signs and symptoms of myotonia and muscle stiffness in 13 patients with myotonia congenita (MC) who were assessed at baseline and 2, 4, and 5 weeks. Ranolazine was started after baseline assessment (500 mg twice daily), increased as tolerated after week 2 (1,000 mg twice daily), … [Read more]

Is RIG-I staining a reliable biomarker of dermatomyositis?

  Dermatomyositis (DM) is inflammatory myopathy or myositis characterised by muscle weakness and skin manifestations. In the differential diagnosis of DM, the evaluation of the muscle biopsy is of importance among other parameters. Perifascicular atrophy in the muscle biopsy is considered a hallmark of DM. However, perifascicular atrophy is not observed in all patients with … [Read more]

International Scientific Congress on spinal muscular atrophy, from 25 to 27 January 2018, in Krakow

SMA Europe welcome you to Krakow for International Scientific Congress on spinal muscular atrophy, which will take place from 25 to 27 January 2018 in Auditorium Maximum of the Jagiellonian University. Spinal muscular atrophy is experiencing exceptional times. Research has progressed significantly, clinical trials have multiplied, new treatments are coming on the market. These results … [Read more]

Newborn screening for lysosomal storage disorders in Illinois

  This study assessed the outcomes of newborn screening for 5 lysosomal storage disorders (LSDs) in the first cohort of infants tested in the state of Illinois. Tandem mass spectrometry was used to assay for the 5 LSD-associated enzymes in dried blood spot specimens obtained from 219 973 newborn samples sent to the Newborn Screening Laboratory … [Read more]

Long-term microdystrophin gene therapy is effective in GRMD

Duchenne muscular dystrophy (DMD) is an incurable X-linked muscle-wasting disease caused by mutations in the dystrophin gene. Gene therapy using highly functional microdystrophin genes and recombinant adeno-associated virus (rAAV) vectors is an attractive strategy to treat DMD. Here, the authors show that locoregional and systemic delivery of a rAAV2/8 vector expressing a canine microdystrophin (cMD1) … [Read more]

Release of the latest newsletter from the Institute

Welcome to our summer issue of the Newsletter! In this edition, two interviews highlight promising results from research teams at the Institute of Myology on both basic and clinical research aspects: the mechanisms of cell migration and improved evaluation of physical activity of patients. Stéphane Vassilopoulos describes the identification of new cell structures used by … [Read more]